Personalized medicine could transform healthcare (Review)

  • Authors:
    • Sunil Mathur
    • Joseph Sutton
  • View Affiliations

  • Published online on: June 2, 2017     https://doi.org/10.3892/br.2017.922
  • Pages: 3-5
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Personalized medicine (PM) is about tailoring a treatment as individualized as the disease. The approach relies on identifying genetic, epigenomic, and clinical information that allows the breakthroughs in our understanding of how a person’s unique genomic portfolio makes them vulnerable to certain diseases. PM approach is a complete extension of traditional approach (One-Size-Fits-All) to increasing our ability to predict which medical treatments will be safe and effective for individual patient, and which ones will not be, based on the patient’s unique genetic profile. Implementation of PM has the potential to reduce financial and time expenditure, and increase quality of life and life extension of patients. Knowledge of PM facilitates earlier disease detection via enhanced use of existing biomarkers and detection of early genomic and epigenomic events in disease development, particularly carcinogenesis. The PM approach predominantly focuses on preventative medicine and favours taking pro-active actions rather than just reactive. This approach delays or prevents the need to apply more severe treatments which are usually less tolerated and with increased quality of life and financial considerations. Increasing healthcare costs have placed additional pressure on government funded healthcare systems globally, especially regarding end of life care. PM may increase the effectiveness of existing treatments and negate the inherent problems associated with non-PM approaches. PM is a young but rapidly expanding field of healthcare where a physician can select a treatment based on a patient’s genetic profile that may not only minimize harmful side effects and guarantee a more successful result, but can be less cost effective compared with a ‘trial-and-error’ approach to disease treatment. The less efficient non-PM (‘trial-and-error’) approach, which can lead to drug toxicity, severe side effects, reactive treatment and misdiagnosis continue to contribute to increasing healthcare costs. Increased patient stratification will allow for the enhanced application of PM and pro-active treatment regimens, resulting in reduced costs and quality of life enhancement.

References

1 

Vogenberg FR, Barash C Isaacson and Pursel M: Personalized medicine: Part 1: Evolution and development into theranostics. P T. 35:560–576. 2010.PubMed/NCBI

2 

Vogenberg FR, Barash CI and Pursel M: Personalized medicine: Part 2: Ethical, legal, and regulatory issues. P T. 35:624–642. 2010.PubMed/NCBI

3 

Sairamesh J and Rossbach M: An economic perspective on personalized medicine. HUGO J. 7:12013. View Article : Google Scholar

4 

Sadée W and Dai Z: Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet. 14:R207–R214. 2005. View Article : Google Scholar : PubMed/NCBI

5 

Tezak Z, Kondratovich MV and Mansfield E: US FDA and personalized medicine: In vitro diagnostic regulatory perspective. Per Med. 7:517–530. 2010. View Article : Google Scholar

6 

Vu T and Claret FX: Trastuzumab: Updated mechanisms of action and resistance in breast cancer. Front Oncol. 2:622012. View Article : Google Scholar : PubMed/NCBI

7 

Romero-Otero J, García-Gómez B, Duarte-Ojeda JM, Rodríguez-Antolín A, Vilaseca A, Carlsson SV and Touijer KA: Active surveillance for prostate cancer. Int J Urol. 23:211–218. 2016. View Article : Google Scholar : PubMed/NCBI

8 

El Miedany Y: MABS: Targeted therapy tailored to the patient's need. Br J Nurs. 24 Suppl 1:S4–S13. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Hammerstrom AE, Cauley DH, Atkinson BJ and Sharma P: Cancer immunotherapy: Sipuleucel-T and beyond. Pharmacotherapy. 31:813–828. 2011. View Article : Google Scholar : PubMed/NCBI

10 

Mali P, Esvelt KM and Church GM: Cas9 as a versatile tool for engineering biology. Nat Methods. 10:957–963. 2013. View Article : Google Scholar : PubMed/NCBI

11 

Cyranoski D: CRISPR gene-editing tested in a person for the first time. Nature. 539:4792016. View Article : Google Scholar : PubMed/NCBI

12 

Reardon S: First CRISPR clinical trial gets green light from US panel. Nature News. simplehttp://www.nature.com/news/first-crispr-clinical-trial-gets-green-light-from-usupanel-1.20137October 8–2016

13 

Kulkarni A and Padilla N: A Strategist's Guide to Personalized Medicine. Strategy and Business. 75:Summer;2014.2014.

14 

Hamburg MA and Collins FS: The path to personalized medicine. N Engl J Med. 363:301–304. 2010. View Article : Google Scholar : PubMed/NCBI

15 

Association of the British Pharmaceutical Industry: The stratification of disease for personalised medicines. simplehttp://www.abpi.org.uk/our-work/library/medical-disease/Pages/personalised-medicines.aspxApril 16–2009

16 

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R and Rosenfeld N: Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nat Rev Cancer. 17:223–238. 2017. View Article : Google Scholar : PubMed/NCBI

17 

Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, De Bruin E, Le Quesne J, Shafi S, et al: Tracking genomic cancer evolution for precision medicine: The lung TRACERx study. PLoS Biol. 12:e10019062014. View Article : Google Scholar : PubMed/NCBI

18 

Hood L and Galas D: The digital code of DNA. Nature. 421:444–448. 2003. View Article : Google Scholar : PubMed/NCBI

19 

Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA and Bradley L: The continuum of translation research in genomic medicine: How can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med. 9:665–674. 2007. View Article : Google Scholar : PubMed/NCBI

20 

Snyderman R: The Case for Personalized Medicine, 201D. 3rd. Washington, DC: pp. 1–32. 2011

21 

U.S. Food and drug Administration: Paving Way for Personalized Medicine: FDA's role in a new era of medical product development. simplehttp://www.fda.gov/downloads/scienceresearch/specialtopics/personalizedmedicine/ucm372421January 10–2014

Related Articles

Journal Cover

July 2017
Volume 7 Issue 1

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Mathur, S., & Mathur, S. (2017). Personalized medicine could transform healthcare (Review). Biomedical Reports, 7, 3-5. https://doi.org/10.3892/br.2017.922
MLA
Mathur, S., Sutton, J."Personalized medicine could transform healthcare (Review)". Biomedical Reports 7.1 (2017): 3-5.
Chicago
Mathur, S., Sutton, J."Personalized medicine could transform healthcare (Review)". Biomedical Reports 7, no. 1 (2017): 3-5. https://doi.org/10.3892/br.2017.922